Edwards Lifesciences Co. (NYSE:EW) Holdings Lifted by ProShare Advisors LLC

ProShare Advisors LLC boosted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.2% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 88,565 shares of the medical research company’s stock after buying an additional 5,944 shares during the quarter. ProShare Advisors LLC’s holdings in Edwards Lifesciences were worth $8,181,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. 9258 Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 24.8% during the fourth quarter. 9258 Wealth Management LLC now owns 10,529 shares of the medical research company’s stock valued at $803,000 after purchasing an additional 2,093 shares during the last quarter. Gryphon Financial Partners LLC lifted its holdings in shares of Edwards Lifesciences by 35.7% during the fourth quarter. Gryphon Financial Partners LLC now owns 6,454 shares of the medical research company’s stock valued at $492,000 after purchasing an additional 1,698 shares during the last quarter. Commerce Bank lifted its holdings in shares of Edwards Lifesciences by 0.6% during the fourth quarter. Commerce Bank now owns 37,938 shares of the medical research company’s stock valued at $2,893,000 after purchasing an additional 216 shares during the last quarter. Orion Portfolio Solutions LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $3,182,000. Finally, Congress Wealth Management LLC DE lifted its holdings in shares of Edwards Lifesciences by 16.3% during the fourth quarter. Congress Wealth Management LLC DE now owns 7,650 shares of the medical research company’s stock valued at $583,000 after purchasing an additional 1,070 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Oppenheimer reaffirmed an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a report on Thursday, September 12th. Stifel Nicolaus reduced their price objective on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research note on Thursday, July 25th. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $85.00 to $70.00 in a research note on Wednesday, September 18th. JPMorgan Chase & Co. downgraded Edwards Lifesciences from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $105.00 to $72.00 in a research note on Thursday, July 25th. Finally, StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Sixteen equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $79.82.

Edwards Lifesciences Stock Down 1.5 %

Shares of EW stock opened at $66.34 on Wednesday. The stock’s 50 day simple moving average is $69.02 and its 200 day simple moving average is $82.43. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a market capitalization of $39.98 billion, a price-to-earnings ratio of 28.59, a PEG ratio of 2.85 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same period last year, the business earned $0.66 EPS. The firm’s revenue was up 6.7% compared to the same quarter last year. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.7 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,250 shares of company stock valued at $1,218,138. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.